L2 Asset Management’s Royalty Pharma RPRX Stock Holding History

L2 Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.25M	Sell	129,324 -17,758	-12%	-$924K	0.75%	44
2026 Q1	$7.06M	Buy	147,082 +1,328	+0.9%	+$58.2K	0.67%	46
2025 Q4	$5.63M	Buy	145,754 +53,539	+58%	+$2.04M	0.75%	45
2025 Q3	$3.25M	Buy	92,215 +85,459	+1,265%	+$3.09M	0.47%	58
2025 Q2	$243K	Buy	+6,756	New	+$224K	0.04%	315
2023 Q2	–	Sell	-67,057	Closed	-$2.42M	–	172
2023 Q1	$2.42M	Buy	67,057 +10,947	+20%	+$406K	1.33%	20
2022 Q4	$2.22M	Sell	56,110 -1,689	-3%	-$70.5K	1.38%	22
2022 Q3	$2.32M	Buy	+57,799	New	+$2.47M	1.6%	18

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

L2 Asset Management's RPRX Position: Q2 2026 in Review

L2 Asset Management reduced its Royalty Pharma (RPRX) stake by 12% in Q2 2026, selling an estimated $924K and leaving 129,324 shares worth $7.25M. The position accounts for 0.75% of the portfolio, ranked #44.

L2 Asset Management first reported a position in RPRX in Q3 2022 and has held it in 8 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

L2 Asset Management held 129,324 shares of Royalty Pharma worth $7.25M as of Q2 2026.
L2 Asset Management sold 17,758 Royalty Pharma shares in Q2 2026, an estimated $924K.
Royalty Pharma made up 0.75% of L2 Asset Management's portfolio in Q2 2026, its #44 holding.
L2 Asset Management first reported a position in Royalty Pharma in Q3 2022 and has held it in 8 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.